

Peter J Shaw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7229452/publications.pdf>

Version: 2024-02-01

193
papers

6,964
citations

76031

42
h-index

78623

77
g-index

199
all docs

199
docs citations

199
times ranked

8033
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	4
2	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. <i>British Journal of Cancer</i> , 2022, 127, 908-915.	2.9	2
3	Donor-derived T cells specific for tumor antigen and multiple pathogens for prevention of relapse and infection after haemopoietic stem cell transplant (HSCT) for myeloid malignancies (the INTACT) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	16
4	Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. <i>Blood Advances</i> , 2022, 6, 4949-4966.	2.5	16
5	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 295-307.	0.8	163
6	Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2021, 223, 1564-1575.	1.9	21
7	A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders. <i>Transfusion</i> , 2021, 61, 894-902.	0.8	2
8	Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells. <i>Blood</i> , 2021, 138, 1504-1509.	0.6	86
9	Effectiveness of early hematopoietic stem cell transplantation in preventing neurocognitive decline in aspartylglucosaminuria: A case series. <i>JIMD Reports</i> , 2021, 61, 3-11.	0.7	2
10	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	0.8	19
11	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. <i>Human Mutation</i> , 2021, 42, 1367-1383.	1.1	11
12	Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1043-1056.	1.3	13
13	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	0.6	65
14	Good Engraftment but Quality and Donor Concerns for Cryopreserved Hemopoietic Progenitor Cell Products Collected During the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1022.e1-1022.e6.	0.6	11
15	Outcomes of pediatric patients with therapy-related myeloid neoplasms. <i>Bone Marrow Transplantation</i> , 2021, 56, 2997-3007.	1.3	4
16	Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. <i>Blood</i> , 2021, 138, 255-255.	0.6	0
17	Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia. <i>Frontiers in Pediatrics</i> , 2021, 9, 775485.	0.9	6
18	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13

#	ARTICLE	IF	CITATIONS
19	Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: Risk factors and association with mortality. <i>Journal of Infection</i> , 2020, 81, 882-894.	1.7	9
20	Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2068-2074.	2.0	2
21	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
22	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
23	Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics. <i>Bone Marrow Transplantation</i> , 2020, 55, 1862-1864.	1.3	3
24	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <sc>EBMT</sc> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	2.0	30
25	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	2.5	34
26	Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, Publish Ahead of Print, e1025-e1029.	0.3	6
27	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
28	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). <i>Blood</i> , 2020, 136, 42-43.	0.6	0
29	Donor-Derived T-Cells Specific for WT1 and PRAME in Combination with T-Cells Specific for Multiple Pathogens for Prevention of Relapse and Infection after Haemopoietic Stem Cell Transplant (HSCT) for Acute Myeloid Leukaemia (AML) or High-Risk Myelodysplasia (MDS) - (The INTACT Trial). <i>Blood</i> , 2020, 136, 38-38.	0.6	0
30	Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. <i>Vaccine</i> , 2019, 37, 5630-5636.	1.7	11
31	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
32	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1786-1791.	2.0	42
33	Hematopoietic stem cell transplantation for children with acute myeloid leukemia in second remission: A report from the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27812.	0.8	6
34	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	2.5	81
35	Research priorities for childhood chronic conditions: a workshop report. <i>Archives of Disease in Childhood</i> , 2019, 104, 237-245.	1.0	16
36	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27

#	ARTICLE	IF	CITATIONS
37	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 136-146.	1.1	10
38	Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). <i>Blood</i> , 2019, 134, 251-251.	0.6	3
39	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 322-328.e10.	1.5	79
40	Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 169-174.	2.0	4
41	Use of Thiotepa in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: An Australian and New Zealand Children's Haematology/Oncology Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S310.	2.0	0
42	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <i>Blood Advances</i> , 2018, 2, 49-60.	2.5	45
43	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. <i>Haematologica</i> , 2017, 102, 1112-1119.	1.7	30
44	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1320-1326.	2.0	10
45	Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. <i>Blood</i> , 2017, 129, 2771-2781.	0.6	84
46	An HPLC-UV method for determining plasma dimethylacetamide concentrations in patients receiving intravenous busulfan. <i>Biomedical Chromatography</i> , 2017, 31, e3906.	0.8	2
47	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. <i>Clinical Infectious Diseases</i> , 2017, 65, 1819-1828.	2.9	179
48	Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 147-152.	2.0	4
49	Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. <i>Blood Advances</i> , 2017, 1, 2193-2205.	2.5	115
50	Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. <i>Journal of Chromatographic Science</i> , 2016, 54, bm145.	0.7	10
51	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 149-159.	1.1	43
52	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , 2016, 3, e526-e536.	2.2	197
53	Graft Transit Time has no Effect on Outcome in Unrelated Donor Myeloablative Haematopoietic Cell Transplants (HCT) Performed in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S345-S346.	2.0	0
54	Body Composition of Five Year Survivors of Paediatric Haematopoietic Cell Transplantation (HCT) at the Children's Hospital at Westmead (CHW). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S185-S186.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Barriers to Transition in Paediatric BMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S194.	2.0	0
56	Assessing Suitability and Feasibility of Administering Neurocognitive, Sleep and Quality of Life Assessments Among Paediatric Hematopoietic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S186.	2.0	0
57	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. <i>Bone Marrow Transplantation</i> , 2016, 51, 1482-1489.	1.3	28
58	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTc, the I-BFM and the Westhafen-Intercontinental-Group. <i>Blood</i> , 2016, 128, 985-985.	0.6	2
59	A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients. <i>Blood</i> , 2016, 128, 2190-2190.	0.6	0
60	Suboptimal Engraftment Is Associated with Reduced Exposure to Fludarabine Metabolite in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2189-2189.	0.6	0
61	Physical activity and screen-time of childhood haematopoietic stem cell transplant survivors. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2015, 104, e455-9.	0.7	20
62	Persistent <scp>MRD</scp> before and after allogeneic <scp>BMT</scp> predicts relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 395-404.	1.2	66
63	MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis. <i>Blood</i> , 2015, 126, 3727-3727.	0.6	0
64	Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2614-2614.	0.6	1
65	Not too little, not too muchâ€”just right! (Better ways to give high dose melphalan). <i>Bone Marrow Transplantation</i> , 2014, 49, 1457-1465.	1.3	45
66	Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 362-368.	0.3	10
67	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. <i>Lancet, The</i> , 2014, 383, 436-448.	6.3	322
68	Outcomes of Allogeneic Cord Blood Transplantation for Leukodystrophies; A Joint Study of Eurocord and "Inborn Errors WP-EBMT". <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S86-S87.	2.0	0
69	The History of Pediatric Hematopoietic Cell Transplantation Around the World. <i>Pediatric Oncology</i> , 2014, , 1-22.	0.5	1
70	Preparative Regimens. <i>Pediatric Oncology</i> , 2014, , 41-56.	0.5	0
71	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. <i>Blood</i> , 2014, 124, 2570-2570.	0.6	0
72	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1608-1614.	2.0	69

#	ARTICLE	IF	CITATIONS
73	Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 338-343.	2.0	32
74	Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor-Mobilized Hemopoietic Progenitor Cell Products Ex Vivo and Safely Transferred to Stem Cell Transplantation Recipients to Facilitate Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 725-734.	2.0	34
75	Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. <i>Blood</i> , 2013, 121, 3745-3758.	0.6	219
76	Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. <i>Bone Marrow Transplantation</i> , 2013, 48, 1056-1064.	1.3	29
77	Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1046-1058.	2.0	46
78	Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: A report from the Australian and New Zealand Children's Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. <i>Pediatric Transplantation</i> , 2013, 17, 582-588.	0.5	31
79	Influence Of Killer Immunoglobulin-Like Receptor (KIR) and HLA Genotypes On Outcomes After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation For Patients With AML and MDS: A Report From The Center For International Blood and Marrow Transplant Research Immunobiology Working Committee. <i>Blood</i> , 2013, 122, 159-159.	0.6	2
80	A qualitative study investigating knowledge and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children. <i>Vaccine</i> , 2012, 30, 7027-7031.	1.7	9
81	Higher Melphalan Exposure Is Associated with Improved Overall Survival for Myeloma Patients Undergoing Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S207.	2.0	7
82	Outcomes of Haematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders: A Report from ANZCHOG and ABMTRR. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S301.	2.0	0
83	Haemopoietic Stem Cell Transplantation for Children with Haematologic Malignancies in Australia and New Zealand - An ANZCHOG and ABMTRR Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S304.	2.0	0
84	Haematopoietic Stem Cell Transplantation Outcomes in Primary Immunodeficiency: A Report from ANZCHOG and ABMTRR. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S305.	2.0	0
85	European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL (2011). <i>Transplant Infectious Disease</i> , 2012, 14, 555-563.	0.7	224
86	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 331-345.	1.6	115
87	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4351-4357.	0.8	124
88	Evaluation of HLA Matching Requirements in Unrelated Hematopoietic Stem Cell Transplantation for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S173.	2.0	1
89	Not Getting High on Busulfan: A Novel Approach to Avoid High Busulfan Levels in Adults and Children Undergoing HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S315-S316.	2.0	0
90	Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysaccharidosis Type VI. <i>JIMD Reports</i> , 2011, 2, 103-106.	0.7	15

#	ARTICLE	IF	CITATIONS
91	Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion. <i>Journal of Clinical Oncology</i> , 2011, 29, 441-448.	0.8	30
92	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. <i>Blood</i> , 2011, 118, 3074-3074.	0.6	0
93	Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. <i>Blood</i> , 2010, 115, 519-529.	0.6	110
94	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010, 116, 4007-4015.	0.6	105
95	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 484-497.	1.1	66
96	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 567-579.	1.1	25
97	Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. <i>British Journal of Haematology</i> , 2010, 149, 263-272.	1.2	88
98	Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. <i>Medical Journal of Australia</i> , 2009, 190, 121-125.	0.8	39
99	Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2918-2927.	1.4	16
100	Establishing the role of pre-implantation genetic diagnosis with human leucocyte antigen typing: what place do "saviour siblings" have in paediatric transplantation?. <i>Archives of Disease in Childhood</i> , 2009, 94, 317-320.	1.0	29
101	HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. <i>Biomedical Chromatography</i> , 2009, 23, 92-100.	0.8	22
102	Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. <i>Bone Marrow Transplantation</i> , 2009, 43, 207-215.	1.3	13
103	Safety and tolerability of cidofovir in high-risk pediatric patients. <i>Transplant Infectious Disease</i> , 2009, 11, 373-379.	0.7	54
104	Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. <i>Blood</i> , 2009, 114, 1429-1436.	0.6	78
105	Pediatric BMT for Malignancy Using Zero/One Antigen Mismatched Family Donors or Unrelated Donors Have Similar Outcomes, Both of Which Are Inferior to Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 4.	2.0	1
106	Cord Blood Transplantation for Pediatric Non-Malignant Conditions. , 2009, , 161-194.		0
107	HPLC-fluorescence assay for acyclovir in children. <i>Biomedical Chromatography</i> , 2008, 22, 879-887.	0.8	14
108	Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 50-59.	1.1	37

#	ARTICLE	IF	CITATIONS
109	226: Single Daily Dose (SDD) Busulfan (Bu) in Children: Comparison of Pharmacokinetics (PK) and Engraftment between Acute Leukaemia (AL) and Non Malignant Disease (NM). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 84.	2.0	0
110	Long-term Follow-up of HCV Infected Patients; Updated Results of the EBMT Prospective Study. <i>International Journal of Infectious Diseases</i> , 2008, 12, S20.	1.5	0
111	Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. <i>Leukemia and Lymphoma</i> , 2008, 49, 710-718.	0.6	12
112	A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide, and Cyclophosphamide With Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors—A Pediatric Blood and Marrow Transplant Consortium Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 204-209.	0.3	5
113	Creating Savior Siblings for Transplantation: Discrepancy Between Parental Wishes and Clinical Practice. <i>Blood</i> , 2008, 112, 744-744.	0.6	1
114	Amphotericin B Dose Optimization in Children with Malignant Diseases. <i>Chemotherapy</i> , 2007, 53, 142-147.	0.8	10
115	412: PEG-filgrastim post-chemotherapy to mobilise PBSC in paediatric oncology patients. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 147-148.	2.0	0
116	Ex Vivo Expansion and Prophylactic Infusion of CMV-pp65 Peptide-Specific Cytotoxic T-Lymphocytes following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 707-714.	2.0	122
117	Neuroblastoma and Other Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 286-302.	2.5	104
118	Pharmacokinetics of melphalan in myeloma patients undergoing an autograft. <i>Bone Marrow Transplantation</i> , 2007, 40, 707-708.	1.3	8
119	Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 151-164.	1.1	32
120	Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 165-172.	0.8	22
121	02 Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive <i>Aspergillus</i> infection. <i>International Journal of Infectious Diseases</i> , 2006, 10, S1-S2.	1.5	1
122	Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: A report from the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 20.	2.0	2
123	Successful mobilisation, harvest, and transplant of stem cells following AMD3100 in 3 paediatric patients. The Australian experience. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 157.	2.0	5
124	Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive <i>Aspergillus</i> infection. <i>Pediatric Blood and Cancer</i> , 2006, 47, 327-329.	0.8	18
125	Pancreatitis and adenoviral infection in children after blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 807-811.	1.3	19
126	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 460-464.	3.2	129

#	ARTICLE	IF	CITATIONS
127	Expansion of Functionally Immature Transitional B Cells Is Associated with Human-Immunodeficient States Characterized by Impaired Humoral Immunity. <i>Journal of Immunology</i> , 2006, 176, 1506-1516.	0.4	169
128	Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 935-942.	1.4	98
129	A topotecan-containing induction regimen for treatment of high risk neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 9013-9013.	0.8	13
130	Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 314-324.	1.1	24
131	Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. <i>British Journal of Haematology</i> , 2005, 132, 051220022257011.	1.2	82
132	Adenovirus Isolation Post Blood and Marrow Transplant (BMT) in Australia and New Zealand- Results of a 4 Year Clinical Multi -Institutional Prospective Cohort Study.. <i>Blood</i> , 2005, 106, 79-79.	0.6	1
133	Antifungal guidelines. <i>Internal Medicine Journal</i> , 2004, 34, 585-586.	0.5	0
134	CD34 selection for bone marrow transplants for children with genetic diseases. <i>Bone Marrow Transplantation</i> , 2004, 33, 351-351.	1.3	0
135	Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 867-868.	1.3	27
136	Unrelated cord blood transplant as salvage following non-engraftment of unrelated marrow transplant?. <i>Bone Marrow Transplantation</i> , 2004, 34, 275-276.	1.3	3
137	Busulphan given as four single daily doses of 150µmg/m ² is safe and effective in children of all ages. <i>Bone Marrow Transplantation</i> , 2004, 34, 197-205.	1.3	17
138	Infusion of unwashed umbilical cord blood stem cells after thawing for allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 739-739.	1.3	7
139	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. <i>Experimental Hematology</i> , 2004, 32, 397-407.	0.2	384
140	Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer. <i>Cancer</i> , 2004, 101, 1866-1872.	2.0	26
141	Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. <i>Bone Marrow Transplantation</i> , 2004, 33, 519-529.	1.3	59
142	Superior Survival Associated with Early Lymphocyte Regeneration after Cytoreductive Chemotherapy in Childhood Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2004, 104, 4494-4494.	0.6	0
143	Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. <i>Blood</i> , 2003, 101, 1611-1619.	0.6	28
144	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. <i>Blood</i> , 2003, 102, 4290-4297.	0.6	160

#	ARTICLE	IF	CITATIONS
145	Suspected infection in children with cancer. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 63-67.	1.3	11
146	Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2002, 29, 843-852.	1.3	45
147	Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. <i>Blood</i> , 2002, 100, 2708-2716.	0.6	44
148	Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. <i>Blood</i> , 2002, 99, 3486-3487.	0.6	22
149	Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. <i>Blood</i> , 2002, 100, 774-777.	0.6	41
150	INTERMITTENT 20q- AND CONSISTENT i(7q) IN A PATIENT WITH SHWACHMAN-DIAMOND SYNDROME. <i>Pediatric Hematology and Oncology</i> , 2002, 19, 525-528.	0.3	17
151	Don't assume an α -fetoprotein secreting tumour is of germ cell or hepatic origin. <i>Medical and Pediatric Oncology</i> , 2002, 38, 357-359.	1.0	0
152	Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. <i>British Journal of Haematology</i> , 2002, 117, 444-450.	1.2	148
153	Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor. <i>Bone Marrow Transplantation</i> , 2002, 30, 1-7.	1.3	31
154	Population pharmacokinetics of amphotericin B in children with malignant diseases. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 671-680.	1.1	39
155	<i>Scedosporium</i> infection in immunocompromised patients: Successful use of liposomal amphotericin B and itraconazole. <i>Medical and Pediatric Oncology</i> , 2001, 37, 122-125.	1.0	33
156	Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 479-484.	1.3	262
157	Complex variant t(4;11) characterized by fluorescence in situ hybridization in infant acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2001, 127, 177-180.	1.0	4
158	Improved outcomes of children with malignancy admitted to a pediatric intensive care unit. <i>Critical Care Medicine</i> , 2000, 28, 3718-3721.	0.4	128
159	Searching for a cord blood unit for transplantation based on the unit's cell count. <i>Bone Marrow Transplantation</i> , 2000, 26, 585-586.	1.3	0
160	Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2000, 25, 1087-1092.	1.3	104
161	Amphotericin B in Children with Malignant Disease: a Comparison of the Toxicities and Pharmacokinetics of Amphotericin B Administered in Dextrose versus Lipid Emulsion. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1417-1423.	1.4	60
162	Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. <i>Journal of Paediatrics and Child Health</i> , 1999, 35, 341-345.	0.4	20

#	ARTICLE	IF	CITATIONS
163	Rapid tapering of cyclosporin to maximise the graft-versus-leukaemia effect. Bone Marrow Transplantation, 1999, 23, 632-633.	1.3	3
164	Ganciclovir-induced encephalopathy in a bone marrow transplant recipient. Bone Marrow Transplantation, 1999, 24, 421-423.	1.3	11
165	Application of interphase FISH on direct bone marrow smears for evidence of chimerism in pediatric sex mismatched bone marrow transplantation. Pathology, 1999, 31, 25-28.	0.3	11
166	Complications of central venous access devices in children with and without cancer. Journal of Paediatrics and Child Health, 1997, 33, 509-514.	0.4	22
167	Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: A report from the Australia and New Zealand Children's Cancer Study Group. , 1997, 29, 108-114.		13
168	A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/Progressive or advanced solid tumors of childhood. Cancer, 1997, 80, 489-496.	2.0	26
169	Induction toxicity of a modified Memorial Sloan-Kettering-New York II protocol in children with relapsed acute lymphoblastic leukemia: A single institution study. , 1996, 27, 139-144.		13
170	Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Bone Marrow Transplantation, 1996, 18, 1043-7.	1.3	7
171	Induction toxicity in childhood acute lymphoblastic leukemia: A comparison of two schedules of daunorubicin administration. Medical and Pediatric Oncology, 1995, 24, 18-22.	1.0	6
172	Letter to the editor: "Thoughts from SIOP 1993: Randomised trials of bone marrow transplantation in paediatric malignancy?" Medical and Pediatric Oncology, 1995, 24, 141-142.	1.0	0
173	Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood. Medical and Pediatric Oncology, 1995, 25, 84-89.	1.0	13
174	Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation.. Journal of Clinical Oncology, 1995, 13, 2789-2795.	0.8	33
175	Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.. Journal of Clinical Oncology, 1994, 12, 2138-2145.	0.8	25
176	Acute myeloid leukaemia in patients with trisomy 21 (Down syndrome) treated by bone marrow transplantation. Journal of Paediatrics and Child Health, 1994, 30, 275-277.	0.4	6
177	Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood, 1994, 84, 2357-62.	0.6	19
178	Parvovirus B19 as a cause of chronic anemia in rhabdomyosarcoma. Cancer, 1993, 72, 945-949.	2.0	21
179	Pneumomediastinum complicating childhood acute lymphoblastic leukaemia. Journal of Paediatrics and Child Health, 1993, 29, 350-351.	0.4	0
180	Re: The Necessity Of Contralateral Surgical Exploration In Wilms Tumor With Modern Noninvasive Imaging Technique: A Reassessment, by A.S. Koo, M.A. Koyle, R.S. Hurwitz, D. Weese, H. Applebaum, E.W. Fonkalsrud and R.M. Ehrlich, J. Urol., part 2, 144: 416-417, 1990. Journal of Urology, 1992, 147, 171-171.	0.2	14

#	ARTICLE	IF	CITATIONS
181	Follow-up of patients with one kidney. Lancet, The, 1992, 339, 679-680.	6.3	5
182	Neuroblastoma with intracranial involvement: An ENSG study. Medical and Pediatric Oncology, 1992, 20, 149-155.	1.0	56
183	Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia. Medical and Pediatric Oncology, 1991, 19, 122-125.	1.0	10
184	Pulmonary Infection Mimicking Metastases in Ewinc'S Sarcoma. Pediatric Hematology and Oncology, 1990, 7, 213-215.	0.3	0
185	Ifosfamide in paediatric oncology: tried but not tested?. Lancet, The, 1990, 335, 1022-1023.	6.3	27
186	Use of silver sulphadiazine cream for burns caused by cytotoxicâ€drug extravasation. Medical Journal of Australia, 1988, 148, 657-657.	0.8	1
187	Prediction and prevention of relapse of acute lymphoblastic leukaemia after bone marrow transplantation. British Journal of Haematology, 1986, 64, 179-186.	1.2	22
188	Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplantation, 1986, 1, 201-8.	1.3	40
189	Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplantation, 1986, 1, 193-200.	1.3	20
190	Transient hyperphosphatasaemia.. Archives of Disease in Childhood, 1985, 60, 84-85.	1.0	4
191	NO CONVULSIONS IN CHILDREN ON HIGH-DOSE BUSULPHAN. Lancet, The, 1985, 325, 220.	6.3	5
192	Extrahepatic biliary obstruction due to stone.. Archives of Disease in Childhood, 1984, 59, 896-897.	1.0	5
193	Neonatal herpes simplex pneumonia.. Archives of Disease in Childhood, 1984, 59, 668-670.	1.0	16